CYP51-IN-22
CYP51-IN-22, the non-deuterated analog of CYP51-IN-23-d3 (HY-174353S), is a potent and broad-spectrum CYP51 inhibitor.CYP51-IN-22 inhibits Aspergillus fumigatum with a MIC80 of 1 μg/mL. CYP51-IN-22 can prevent fungal phase transformation and biofilm formation. CYP51-IN-22 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-22 can be used for the study of invasive fungal infections (IFIs).
For research use only. We do not sell to patients.
- Formula: C29H30BrF2N7O2
- Molecular Weight:626.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
CYP51 |
CYP51-IN-22 (Compound V23) (1-16 mL, 48 h) shows broad-spectrum activity against eight fluconazole-resistant fungi with a MIC80 of 1-16 μg/ml[1].
CYP51-IN-22 (2-8×MIC, 0-24 h) exhibits fungicidal activity in a dose-dependent manner against C. parapsilosis: The longer the time, the higher the concentration, and the better the fungicidal activity[1].
CYP51-IN-22 (0-32 mL, 6 h) shows effectiveanti-biofilm inhibition activity in the biofilm growth stage of C. glabrata and C. neoformans[1].
CYP51-IN-22 (2-8 mL, 4 h) can inhibit the phase transition of C. albicans[1].
CYP51-IN-22 (10 μM, 4 h) has no significant toxicity effect on HUVEC (human umbilical vein endothelial cell line) and SH-SY5Y (neuroblastoma cell line) [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Candida parapsilosis was injected through the tail vein to establish a mouse (ICR, 4-6 weeks) candida-infection model
-
Dosage:5 mg/kg, 10 mg/kg
-
Administration:Intraperitoneal injection (i.p.) or gavage (p.o.) 4 h after infection
-
Result:Reduced the renal fungal load in mice and was better than the positive control fluconazole.
Dose-dependent, and the efficacy of intraperitoneal injection was better than that of oral gavage administration.
Chemical Information
-
Molecular Weight 626.50
-
Formula C29H30BrF2N7O2
-
SMILES
FC1=CC(F)=CC=C1C(CN(C)CC2=CC=C(N3CCN(C(C4=CC(Br)=CC=C4)=O)CC3)C=C2)(O)CN5C=NN=N5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CYP51-IN-22 Related Classifications
HY-174353 Related Classifications
Powered by Bioz